Ignite Creation Date:
2025-12-24 @ 6:43 PM
Ignite Modification Date:
2026-01-05 @ 6:13 PM
Study NCT ID:
NCT03327857
Status:
COMPLETED
Last Update Posted:
2023-01-19
First Post:
2017-10-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
Sponsor:
AltruBio Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-31
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-31
Completion Date Type:
ACTUAL
First Submit Date:
2017-10-13
First Submit QC Date:
None
Study First Post Date:
2017-11-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-17
Last Update Post Date:
2023-01-19
Last Update Post Date Type:
ACTUAL